Chronic Pain – Access & Reimbursement – Detailed, Expanded Analysis (EU5)

The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The mature prescription analgesic landscape, while crowded with many well-established treatment options, nevertheless presents commercial opportunities for drug developers because treatment of refractory chronic pain remains a challenge. However, new therapies will need to compete for positioning in an already-complex treatment algorithm, and a growing generic presence across multiple drug classes—coupled with evolving access and reimbursement requirements throughout the EU5—will result in increasing market access challenges for branded therapies.

Table of contents